Who are Custodiol HTK's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HTK Custodiol, Custodiol Htk Soln, Custodiol-N, Hydrogen-Rich Celsior Solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/custodiol-htk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Custodiol HTK — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Custodiol HTK (Custodiol HTK) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Organ preservation solution. Area: Transplantation.

phase 3 Organ preservation solution Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Custodiol HTK (Custodiol HTK) — Marc Sakwa, MD. Custodiol HTK is an organ preservation solution that maintains cellular viability and reduces ischemic injury during organ transplantation by providing a balanced electrolyte composition and metabolic substrates.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Custodiol HTK TARGET	Custodiol HTK	Marc Sakwa, MD	phase 3	Organ preservation solution
HTK Custodiol	HTK Custodiol	Rigshospitalet, Denmark	marketed	Organ preservation solution
Custodiol Htk Soln	Custodiol Htk Soln	Lourdes Montero Cruces	marketed	Organ preservation solution
Custodiol-N	Custodiol-N	Dr. F. Köhler Chemie GmbH	phase 3	Organ preservation solution
Hydrogen-Rich Celsior Solution	Hydrogen-Rich Celsior Solution	RenJi Hospital	phase 3	Organ preservation solution	Reactive oxygen species (ROS), particularly hydroxyl radicals

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Organ preservation solution class)

Dr. F. Köhler Chemie GmbH · 1 drug in this class
Lourdes Montero Cruces · 1 drug in this class
Marc Sakwa, MD · 1 drug in this class
RenJi Hospital · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Custodiol HTK — Competitive Intelligence Brief. https://druglandscape.com/ci/custodiol-htk. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing